Talk:Umbralisib

This is the talk page for discussing improvements to the Umbralisib article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Umbralisib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Also in a trial of a triplet regimen

[1] with ublituximab and ibrutinib, in various subtypes of non-Hodgkin lymphoma (NHL). - Need RS and NCT# - Rod57 (talk) 19:02, 20 December 2017 (UTC)[reply]

Disagree with adding the barrientos article

The commentary by Jacqueline Barrientos is biased in regard to only focusing on Idelalisib as being an approved Pi3k medication, although last year another Pi3k inhibitor, copanlisib, has been approved by US FDA for treatment of Follicular lymphoma (is an NHL type) that relapsed after two prior systemic therapies. Please note that Ms Barrientos is heavily Coi'd (see her reporting in the respective commentary), amongst it Gilead, the producer of Idelalisib. Given her neglecting of another approved pi3k inhibitor in NHL, as well as her financial COI, I think this article should not be referred here for reasons of neutrality!

Instead, if you think a citation is needed, I propose to cite the actual Umbralisib article (and not the commentary).

(And for transparency, please see my own coi on my user page, as Copanlisib is produced by Bayer). Wowbagger2 (talk) 19:42, 1 March 2018 (UTC)[reply]